Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 9/20 | 0.68 |
| ▸ | CDK4 | P11802 | 4/20 | 0.68 |
| ▸ | CCND3 | P30281 | 3/20 | 0.68 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | BCR | P11274 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955040 | 0.90 | GSK3B (0.68) | PLK1GSK3BCDK4CCND3CAMK2D | |
| SCHEMBL30554522 | 0.87 | PLK1 (0.65) | PLK1GSK3BCDK4CCND3CAMK2D | |
| SCHEMBL25980185 | 0.87 | PLK1 (0.65) | PLK1GSK3BCDK4CCND3CAMK2D | |
| SCHEMBL2946515 | 0.85 | PLK1 (0.77) | PLK1GSK3BCDK4CCND3CAMK2D | |
| SCHEMBL21074128 | 0.83 | BRAF (0.65) | GSK3BCDK4CCND3CDK2ABL1 | |
| SCHEMBL4732841 | 0.81 | PLK1 (1.00) | PLK1GSK3BCDK4CCND3CAMK2D | |
| SCHEMBL19966865 | 0.81 | BRAF (0.68) | GSK3BCDK4CCND3CAMK2DABL1 | |
| SCHEMBL30335652 | 0.81 | PLK1 (0.60) | PLK1GSK3BCDK4CCND3CAMK2D | |
| SCHEMBL25068552 | 0.81 | CDK4 (1.00) | PLK1GSK3BCDK4CCND3CAMK2D | |
| SCHEMBL30847276 | 0.80 | CDK4 (0.52) | GSK3BCDK4CCND3CDK2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1933839-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | Novartis AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | BULUSU MURTY (AT) | 2005-06-02 | — | — | US | disclosed |
| EP-1474146-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003063871-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | IFNG, IL2, LY96 | PLK1 1369/4885GSK3B 4583/4885CDK4 2063/4885 |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | PLK1 1234/4885GSK3B 2749/4885CDK4 692/4885 |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | FCER2, SELP, FCGR2A | PLK1 1234/4885GSK3B 2749/4885CDK4 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.